Kesimpta
Kesimpta is a medicine authorised by Swissmedic under authorisation number 67758. The authorisation holder is Novartis Pharma Schweiz AG. The medicinal product code is Biotechnological medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 01 February 2021 and the authorisation is valid without a time limit. ATC code L04AG12 places the medicine in the group Immunosuppressants.
| Authorisation number | 67758 |
|---|---|
| Name | Kesimpta |
| Full name | Kesimpta, Injektionslösung in Fertigpen |
| Authorisation holder | Novartis Pharma Schweiz AG |
| Medicinal product code | Biotechnological medicines |
| Dispensing category | B · Prescription only |
| ATC code | L04AG12 |
| First authorisation | 01 February 2021 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Kesimpta, Injektionslösung in Fertigpen | B | 01 February 2021 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 1 | Stück | L04AG12 | 01.99.0. | B |
Scroll the table sideways
Other medicines from this authorisation holder
Frequently asked questions
Is Kesimpta authorised in Switzerland?
Yes. Kesimpta is authorised by Swissmedic under authorisation number 67758, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Kesimpta have?
Kesimpta is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Kesimpta?
The authorisation holder is Novartis Pharma Schweiz AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.